Dr. William Gradishar Discusses 10 Years Of Adjuvant Tamoxifen

Dr. William Gradishar Discusses 10 Years of Adjuvant Tamoxifen

Dr. William Gradishar on the Standard Duration of Tamoxifen

Targeted Oncology

Dr. Gradishar Comments on the Treatment of Early Stage Breast Cancer With Endocrine Therapy

Dr. William Gradishar Discusses the Eribulin and Capecitabine 301 Study

Dr. Debu Tripathy on 10 Versus 5 Years of Adjuvant Tamoxifen

Dr. Gradishar Discusses Advances in the Treatment of HER2-Positive Breast Cancer

Targeted Oncology

Dr. William Gradishar on the Importance of Enriching Clinical Trials

Adjuvant Therapy | 2023 KU Breast Cancer Year in Review Conference

Total Health | Oncology

Richard Gray on the Safety and Efficacy of 10-Years of Adjuvant Tamoxifen

Targeted Oncology

Advances in the teatment of high-risk early-stage hormone receptor positive breast cancer

Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines

New Insights from SABCS 2016 on Adjuvant Therapy for HR+ Breast Cancer

2012 SABCS - Should Patients Take 10 Years of Tamoxifen After Breast Cancer?

Ten years of tamoxifen slashes breast cancer risk

MDedge: news and insights for busy physicians

Julie R. Gralow, MD: The Atlas Trial. Tamoxifen For Five Years or Ten Years?

Vital Options International

Dr. Gradishar Discusses the Results of the BOLERO-1 Trial

Drs. Hamilton, Gradishar, Rugo, & Schmid discuss #BreastCancer at #SABCS22 - http://bit.ly/3zEdPM8

PeerView Oncology

San Antonio Roundtable, Part 1: Fulvestrant Dose and Tamoxifen Duration

MDedge: news and insights for busy physicians

SABCS 2017 roundtable with Dr. Hope S. Rugo and Dr. William J. Gradishar

MDedge: news and insights for busy physicians

Do Bisphosphonates Reduce Cancer Risks?

MDedge: news and insights for busy physicians